Optimizing Treatment of Adhesive Small Bowel Obstruction
The Use of Nasogastric Tubes And Water-Soluble Contrast In The Management Of Small Bowel Obstruction: A Feasibility Study
University of California, Los Angeles
40 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
Small bowel obstruction (SBO) is one of the most common causes of serious gastrointestinal disease in the US. Adhesion-related SBO (aSBO) is usually treated by the placement of a nasogastric tube (NGT) to decompress the stomach, administration of intravenous (IV) fluids and observation by a surgical team. The purpose of this feasibility study is to determine the potential for implementation of treatment protocols for aSBO and determine the feasibility of randomizing patients with aSBO to receive or not receive NGTs or water-soluble contrast (WSC). The investigators will also determine the ability to measure HRQOL as a main outcome for the treatment of aSBO. The studies outlined in this research program intend to address gaps in knowledge about how to determine who benefits from NGT placement, who can be managed without them, how to objectively determine when a bowel obstruction has resolved, how to reintroduce feeding to patients with aSBO, what criteria should be used for hospital discharge and what role cathartics such as WSC contrast have in the management of aSBO. This feasibility study will enroll a limited number of patients (n=40) who will be followed for up to 30 days.
Eligibility
Inclusion Criteria2
- Male or female ≥18 years of age.
- Documentation of aSBO as evidenced by one or more clinical features meeting the following criteria: Nausea, emesis, abdominal pain, distended abdomen CT evidence of aSBO
Exclusion Criteria8
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
- Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
- Unstable angina or recent myocardial infarction (MI)/stroke within 6 months
- Nonadhesive SBO
- Paralytic Ileus
- Incarcerated hernia
- Fecal impaction
- Intra-abdominal malignancy Early aSBO within 4 weeks of a prior abdominal operation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration of WSC (Gastrografin) 2 hours after placement of NGT.
Administration of Saline 2 hours after placement of NGT.
Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06182319